---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124576"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:04:12.463729+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BridgeBio posts Q3 net loss of $162M; acoramidis PDUFA set for Nov 29, 2024

## Summary
- Net loss per share of $0.86; revenue $2.7M vs $4.1M YoY; operating expenses $194.5M.
- Cash, equivalents, and short-term restricted cash $405.7M; expects $500M milestone from acoramidis upon FDA approval.
- FDA accepted acoramidis NDA; PDUFA date November 29, 2024; 42-month OLE data to be presented at AHA.
- FDA granted Breakthrough Therapy Designation to oral infigratinib for achondroplasia.
- Phase 3 FORTIFY trial for LGMD2I/R9 enrollment completed; interim analysis expected in 2025.

## SEC filing metadata
- accession: 0000950170-24-124576
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/0000950170-24-124576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124576
- JSON: https://secwatch.observer/filing/0000950170-24-124576.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.